Last updated on November 2019

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis


Brief description of study

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.

CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Clinical Study Identifier: NCT02158858

Find a site near you

Start Over

Massachusetts General Hospital

Boston, MA United States
9.4miles
  Connect »